Hyperpolarized C 13 Pyruvate Imaging for Brain Cancer
Trial Summary
What is the purpose of this trial?
This trial studies how an imaging agent, hyperpolarized carbon C 13 pyruvate, works in diagnosing glioma in patients with brain tumors. Giving hyperpolarized carbon C 13 pyruvate before an advanced imaging technique called a magnetic resonance spectroscopic imaging (MRSI) scan may help researchers better diagnose glioma in patients with brain tumors.
Do I need to stop my current medications to participate in the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Hyperpolarized Carbon C 13 Pyruvate Imaging for Brain Cancer?
Research shows that hyperpolarized [1-13C]pyruvate can help detect treatment responses in brain tumors by highlighting changes in tumor metabolism, which is not easily visible with other imaging methods. This technique has been used to track tumor metabolism in both brain and breast cancer, suggesting its potential usefulness in monitoring how well treatments are working.12345
Is Hyperpolarized C 13 Pyruvate Imaging safe for humans?
How does hyperpolarized C 13 pyruvate imaging differ from other brain cancer treatments?
Hyperpolarized C 13 pyruvate imaging is unique because it uses a special form of MRI to track the metabolism of pyruvate in real-time, providing detailed insights into tumor metabolism that other imaging methods can't offer due to high background signals in the brain. This technique allows for non-invasive monitoring of how brain tumors respond to treatments, which is not possible with standard imaging techniques.1491011
Research Team
Dawid Schellingerhout
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
This trial is for adults over 18 with suspected or confirmed primary brain tumors who are candidates for tumor removal surgery. They must be able to undergo MRI scans and have a kidney function test (GFR) above 60. People with pacemakers, metal in their body, previous brain tumor treatments, or certain heart conditions cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive hyperpolarized carbon C 13 pyruvate intravenously and undergo an MRSI scan
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants' genomic, pathology, and imaging findings are assessed over time
Treatment Details
Interventions
- Hyperpolarized Carbon C 13 Pyruvate
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator